Nectar Lifesciences has cleared a share buyback worth ₹81 crore, according to a filing on December 3, 2025. The company plans to repurchase 3 crore equity shares at ₹27 each, using the tender offer method.
The buyback represents 13.38% of its paid-up equity capital as of March 2025. Promoters and the promoter group have stated they will not take part in the offer.
The buyback falls within the regulatory limit of 10% of paid-up capital and free reserves. Costs such as brokerage, filing fees, taxes and other charges are not part of the ₹81 crore amount.
Master Capital Services Limited has been appointed as the merchant banker. The company has fixed December 24, 2025, as the record date to identify eligible shareholders.
Pre-buyback, the company has 22.43 crore shares on record. If the full 3 crore shares are accepted, the total would fall to 19.43 crore shares.
Based on the table dated November 28, 2025, promoter shareholding would increase from 44.91% to 51.84% after the reduction in share count. Public shareholding would shift from 55.09% to 48.16% under the same assumption.
The board has also appointed Sushil Kapoor as an Additional Director and Wholetime Director (Finance) from December 4, 2025, for a 3-year term subject to shareholder approval.
He is a chartered accountant and company secretary with more than 38 years of experience in finance roles across several companies.
The resolutions will now move to shareholders through a postal ballot for formal approval where required. The company has also released the pre- and post-buyback shareholding pattern and other statutory disclosures as part of its exchange filing.
Read More: JSW Steel Forms 50:50 JV with JFE Steel; JFE to Invest ₹15,750 Crore!
As of December 04, 2025, 09:36 am, Nectar Lifesciences share price was trading at ₹20.25, a 13.25% increase from the previous closing price.
The filing sets out the size, structure, and timeline of the proposed buyback, along with changes in board composition and related regulatory steps.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Published on: Dec 4, 2025, 11:19 AM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
EN